The health care industry is taking a stand against the maker of EpiPen

Dan Gorenstein Jan 13, 2017
HTML EMBED:
COPY

The health care industry is taking a stand against the maker of EpiPen

Dan Gorenstein Jan 13, 2017
HTML EMBED:
COPY

As we all know, the maker of EpiPen, Mylan, has engaged in price gouging. But this week, the larger health care industry sent a strong message that they are not going to stand for it. On Wednesday, Cigna announced it would only cover the generic version of EpiPen. On Thursday, CVS announced a deal with an EpiPen competitor that could hurt Mylan’s generic sales. It’s a strange and unusual kind of pushback. The kind we rarely see in the health care industry.

Click the above audio player to hear the full story.


We’re here to help you navigate this changed world and economy.

Our mission at Marketplace is to raise the economic intelligence of the country. It’s a tough task, but it’s never been more important.

In the past year, we’ve seen record unemployment, stimulus bills, and reddit users influencing the stock market. Marketplace helps you understand it all, will fact-based, approachable, and unbiased reporting.

Generous support from listeners and readers is what powers our nonprofit news—and your donation today will help provide this essential service. For just $5/month, you can sustain independent journalism that keeps you and thousands of others informed.